The histone modification change between PRC2-wt and PRC2-loss in human MPNST cancer cells

Default Boolean Operator: Terms in a search string will be connected by the AND operator, EXAMPLE: searching genomic melanoma will produce the same results as genomic AND melanoma .
AND, OR, NOT: Combine terms in a search with the boolean operators AND (to add specificity), OR (to broaden), or NOT (to eliminate a term). Operators must be capitalized (all other search terms are not case-sensitive).
Wild Card: Add wild card symbols * (open-ended) and ? (single character) to truncate terms. EXAMPLE: searching gen* shows results for 'gene', 'genetic', 'genomic, etc. Searching gene? returns results for 'gene' or 'genes' but not for 'genome'.
Phrase Searching: Enclose search in quotation marks "keyword or search term" to search for an exact phrase. EXAMPLE: "transcription factors" returns results for records where transcription is immediately followed by the word factors .
Diacritics: Words containing diacritics translate those characters to non-diacritic form. EXAMPLE: massague returns results for Massague&#769 .
Filter by: Located on the homepage (left panel), use filters to search for records or narrow the search. From search results page, filters can be removed by clicking on the term at the top of the page.

UID: 11330

Author(s): Chi, Ping*, Chen, Yu*, Yan, Juan* * MSK affiliated

Description: Description from GEO:

"PRC2-isogenic human malignant peripheral nerve sheath tumor (MPNST) M3 cells were generated through CRISPR/Cas9-mediated knockout of the PRC2 core component, SUZ12. PRC2 loss leads to global loss of H3K27me3, which causes H3K27ac redistribution and also affect other histone modification, e.g., H3K36me2/3."

Overall design from GEO:

"PRC2-isogenic human MPNST M3 cells (sgCon, sgSUZ12) were used for CUT&RUN with H3K27me3, H3K27ac, H3K36me2, H3K36me3."

Subject of Study

Subject(s)

OncoTree Cancer Type(s)

Malignant Peripheral Nerve Sheath Tumor

Do you have or know of a dataset that should be added to the catalog? Let us know!